Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
ID: 344598Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344598

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-026.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled “Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)” aimed at supporting time-sensitive ancillary studies that leverage resources from active clinical projects related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and government agencies, with a funding limit of $400,000 over a two-year period. This initiative emphasizes innovative research that enhances the understanding of diseases while ensuring that ancillary studies do not disrupt parent projects, encouraging interdisciplinary collaboration. Interested applicants should note that the application deadline is December 5, 2025, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-026.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-026.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), issued a funding opportunity titled “Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed).” The announcement aims to support time-sensitive ancillary studies related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), leveraging resources from active clinical projects. Eligible applicants include various higher education institutions, nonprofits, for-profit organizations, and government entities, with direct costs limited to $400,000 over two years. Key points of the application include a focus on innovative research that enhances the understanding of diseases, emphasizing the importance of well-characterized patient cohorts. Ancillary studies must not disrupt parent projects and are encouraged to collaborate across disciplines. The review process will be accelerated for applications showing clear time sensitivity related to the parent project. Notably, the FOA prohibits clinical trials and requires adherence to NIH policies. Critical submission requirements include timely registration, adherence to application instructions, and obtaining approval from parent study committees. The objectives are to promote groundbreaking research that identifies new targets for disease diagnosis, treatment, and prevention while efficiently using existing resources.
    Similar Opportunities
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Ancillary Studies to Ongoing Clinical Projects funding opportunity (PAR-23-025), aimed at supporting time-sensitive ancillary studies that enhance scientific knowledge related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). These studies must utilize existing cohorts, data, and biological samples to explore novel research questions that extend beyond the scope of the parent projects, with an emphasis on collaboration between junior and senior researchers. Grants may provide up to $300,000 per year for a duration of up to four years, with applications accepted until December 6, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding opportunities through the "Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases" program, specifically under the R61 Clinical Trial mechanism. This initiative aims to support short-term exploratory clinical trials that investigate treatments for rheumatic, musculoskeletal, and skin conditions, with a focus on diverse therapeutic approaches. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and state and local governments, with a maximum budget of $600,000 for a three-year project, not exceeding $300,000 in any single year. Applications must be submitted electronically via Grants.gov, with key deadlines starting from February 4, 2024, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) (Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition Small Grant Program (R03) aimed at supporting recipients of K01, K08, K23, and K25 awards from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This program allows eligible awardees, specifically those in their second to fourth award year who do not yet hold independent R01 grants, to request up to $100,000 in direct costs over a two-year period to enhance their research capabilities, focusing on pilot studies, methodology development, and secondary data analysis, while explicitly excluding clinical trials. The initiative is designed to foster the development of early-career scientists and strengthen the research landscape by generating additional publications and data necessary for future R01 grant applications. Interested applicants must submit their proposals by February 19, 2025, and can find more information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21), aimed at supporting innovative early-stage research projects in the biomedical, behavioral, and clinical fields. This funding opportunity is specifically designed for basic experimental studies involving human participants, with a focus on developing novel techniques or methodologies that can significantly advance scientific understanding. Eligible applicants, including small businesses and various institutions, can receive funding of up to $275,000 over a two-year period, with applications accepted on a rolling basis until the close date of January 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PA-20-196.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.